Search clinical trials for: Relapse Risk

Total 21796 results

Apollo Therapeutics Ltd

Not yet recruiting

A Study to Investigate APL-4098 Alone and/or in Combination With Azacitidine in R/R AML and High-Risk MDS

Myelodysplastic Syndrome With Excess Blasts | Acute Myeloid Leukemia, in Relapse | Acute Myeloid Leukemia Refractory | Myelodysplastic Syndrome Acute Myeloid Leukemia
Ruijin Hospital

Not yet recruiting

CAR-T Following ASCT for Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (R/R B-NHL) With High-Risk Prognostic Factors

B-NHL, Extranodal, TP53 Alterations, Bulky Mass
Second Affiliated Hospital, School of Medicine,...
Ningbo Medical Center Lihuili Hospital; Huizhou Municipal Central Hospital; Taizhou... and other collaborators

Recruiting

Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI

Diffuse Large B-cell Lymphoma

China
The Lymphoma Academic Research Organisation
Lymphoma Study Association

Not yet recruiting

Golcadomide Post-CAR T-cell in R/R Aggressive Large B-cell Lymphoma Patients With High Risk of Relapse

Refractory High Grade B-Cell Lymphoma | Diffuse Large B-cell Lymphoma Refractory | Refractory Transformed B-cell Non-Hodgkin Lymphoma | Refractory Primary Mediastinal Large B-Cell Lymphoma

France
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Poland
GluBio Therapeutics Inc.

Recruiting

A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
University of Cagliari
Università di Napoli Federico II; Università della Campania Luigi Vanvitelli

Not yet recruiting

Machine learnINg for the rElapse Risk eValuation in Acute Biliary Pancreatitis. (MINERVA)

Acute Pancreatitis | Pancreatitis Biliary | Pancreatitis Relapsing | Pancreatitis Due to Gallstones

Italy
Central Institute of Mental Health, Mannheim

Recruiting

Neurobehavioral Profiles of Adaptive Stress Responses in Individuals With Alcohol Use Disorder (A03)

Risk Behavior | Alcohol Use Disorder | Craving | Relapse | Stress Reaction | Social Stress | Addiction, Alcohol

Germany
H. Lee Moffitt Cancer Center and Research Institute
Kite, A Gilead Company

Recruiting

Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL

Large B-cell Lymphoma | Relapsed Non-Hodgkin Lymphoma

United States
Assistance Publique - Hôpitaux de Paris

Not yet recruiting

Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis (CMV CAR-T)

B Cell Lymphoma | Acute Leukemia | Cytomegalovirus Infections
Vincerx Pharma, Inc.

Recruiting

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

Acute Myeloid Leukemia | B-cell Acute Lymphoblastic Leukemia | High-risk Myelodysplastic Syndrome

United States
Mayo Clinic

Recruiting

Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors

Malignant Solid Neoplasm | Hematopoietic and Lymphoid System Neoplasm | Obesity-Related Malignant Neoplasm

United States
Sun Yat-sen University
Hainan General Hospital

Recruiting

Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma

Neuroblastoma

China
Schrödinger, Inc.

Recruiting

Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-Risk and Very High-Risk Myelodysplastic Syndromes

United States
Peter MacCallum Cancer Centre, Australia

Recruiting

Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma Refractory

Australia
PureTech

Recruiting

A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

MDS | AML, Adult Recurrent

United States
Ho Joon Im

Not yet recruiting

Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia (ReCALL)

Acute Lymphoid Leukemia

Korea, Republic of
Stanford University
Kite Pharma

Recruiting

Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel

Non-Hodgkin Lymphoma | Large B-cell Lymphoma

United States
Pfizer

Recruiting

A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

ACUTE LYMPHOBLASTIC LEUKEMIA

Italy, Spain, Belgium, Germany, Hungary, Switzerland, Norway, Austria, France, Czechia, Finland, Netherlands, Sweden, Israel, Poland, Denmark, Greece, Slovakia
University Hospital, Toulouse

Recruiting

A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse (MIRACLE)

Non-small Cell Lung Cancer Stage IIIA

France
Chordia Therapeutics, Inc.
Theradex

Recruiting

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
Stephan Grupp MD PhD
Children's Hospital of Philadelphia; University of Pennsylvania; Tmunity Therapeutics

Recruiting

GPC2 CAR T Cells for Relapsed or Refractory Neuroblastoma (GPC2)

Refractory Neuroblastoma | High-risk Neuroblastoma | Relapsed Neuroblastoma

United States
Centre Hospitalier Henri Laborit

Recruiting

Effect of the Enriched Environment on the Risk of Relapse (ENVELMIND)

Alcoholic Relapse

France
Centre for Addiction and Mental Health
Janssen Inc.

Recruiting

Risk of Breakthrough Symptoms With Long-Acting Injectable Medications

Schizophrenia | Schizophrenia Relapse

Canada
Arcellx, Inc.

Recruiting

Phase I Study of Cell Therapies for the Treatment of Patients With Relapsed or Refractory AML or High-risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndromes

United States
iCell Gene Therapeutics
iCar Bio Therapeutics

Not yet recruiting

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

High Risk Hematologic Malignancies | Relapsed and/or Refractory Acute Myeloid Leukemia

China
Children's Hospital Los Angeles
United Therapeutics

Recruiting

Rapid Administration Pilot for Infusing Dinutuximab (RAPID)

Neuroblastoma

United States
Emory University

Recruiting

Allogeneic Expanded Gamma Delta T Cells With GD2 Chemoimmunotherapy in Relapsed or Refractory Neuroblastoma (Aflac-NBL-2002)

Neuroblastoma | Refractory Neuroblastoma | Relapsed Neuroblastoma

United States
Andrew E. Place, MD
University of Colorado, Denver; AbbVie; Boston Children's Hospital; Gateway for... and other collaborators

Recruiting

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Acute Lymphoblastic Leukemia, in Relapse | Therapy-Related Myelodysplastic Syndrome | Acute Leukemia of Ambiguous Lineage | Acute Leukemia of Ambiguous Lineage in Relapse | Myelodysplastic Syndromes, Previously Treated | Acute Lymphoblastic Leukemia With Failed Remission | Myelodysplastic Syndromes... and other conditions

United States
Jagiellonian University

Recruiting

Immunotherapy With Dinutuximab Beta in Combination With Chemotherapy for the Treatment of Patients With Primary Neuroblastoma Refractory to Standard Therapy and With Relapsed or Progressive Disease (ChIm-NB-PL)

High-Risk Neuroblastoma

Poland
Zhujiang Hospital

Recruiting

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

Leukemia, Myeloid, Acute

China
Fudan University

Recruiting

R-CDOP Combined With Intrathecal Methotrexate for DLBCL Patients With High-risk of CNS Relapse

Diffuse Large B-cell Lymphoma

China
Massachusetts General Hospital
Patient-Centered Outcomes Research Institute

Recruiting

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia (SCOPE-L)

High Risk Acute Myeloid Leukemia | Relapsed Adult AML | Primary Refractory Acute Myeloid Leukemia

United States
iCell Gene Therapeutics
iCar Bio Therapeutics

Recruiting

CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma

Relapsed/Refractory, High Risk Hematologic Malignancies | T-ALL/Lymphoma

China
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Recruiting

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). (pediTACTAL)

Hodgkins Lymphoma | Non Hodgkins Lymphoma

United States
HBI Solutions Inc.
mProbe Inc.

Not yet recruiting

Cohort Study to Evaluate the Relapse Risk Test in Colorectal Cancer

Colorectal Cancer
M.D. Anderson Cancer Center

Recruiting

Phase I/II Study of CD5 CAR Engineered IL15-Transduced Cord Blood-Derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Hematological Malignances

Hematological Malignancy

United States
Sanofi

Recruiting

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Myelodysplastic Syndromes | Acute Lymphocytic Leukaemia | Acute Myeloid Leukaemia Refractory | Blastic Plasmacytoid Dendritic Cell Neoplasia

Netherlands, France, United States, Australia, China
Federal Research Institute of Pediatric Hematology...

Recruiting

Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Acute Lymphoblastic Leukemia, in Relapse | Non-hodgkin Lymphoma | High Risk Acute Myeloid Leukemia | High Risk Acute Lymphoblastic Leukemia | Acute Biphenotypic Leukemia in Relapse

Russian Federation
H. Lee Moffitt Cancer Center and Research Institute
Florida Department of Health

Recruiting

Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center

Recruiting

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
Celgene

Recruiting

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Australia, Spain, Canada, United Kingdom
Jakob Stenman
Novartis; Advanced Accelerator Applications

Recruiting

177Lutetium-DOTATATE in Children With Primary Refractory or Relapsed High-risk Neuroblastoma (LuDO-N)

Neuroblastoma | Neuroblastoma Recurrent

Sweden, Denmark, Lithuania, Norway, Netherlands
Coeptis Therapeutics
Duke University

Recruiting

Safety and Efficacy of Allogeneic NK Cell Infusions in Patients With Relapsed/Refractory AML and High Risk MDS

MDS | AML, Adult Recurrent

United States
Kai Lin Xu; Jun Nian Zheng
First Affiliated Hospital of Zhejiang University; Nantong University; Affiliated... and other collaborators

Recruiting

Clinical Study of CAR-iNKT Cells in the Treatment of Relapsed/Refractory/High-risk B-cell Tumors

B-cell Lymphoma | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

China
Istituto Ortopedico Rizzoli

Recruiting

Metformin as Maintenance Therapy in Patients With Bone Sarcoma and High Risk of Relapse (Metform-Bone)

Osteosarcoma | Ewing Sarcoma

Italy
Hoag Memorial Hospital Presbyterian

Recruiting

PyL in Patients With High Risk and Biochemically Recurrent Prostate Cancer

Prostate Cancer

United States
Giselle Sholler

Recruiting

DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma

Medulloblastoma

United States
Joseph Tuscano
National Cancer Institute (NCI); Seagen Inc.

Recruiting

Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States

Search clinical trials for: Relapse Risk

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations